Scotiabank Cuts Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $300.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective cut by Scotiabank from $310.00 to $300.00 in a report published on Friday morning,Benzinga reports. They currently have a sector outperform rating on the biopharmaceutical company’s stock. Several other research firms have also recently issued reports on ALNY. Chardan Capital reiterated a “buy” rating and […]
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective cut by Scotiabank from $310.00 to $300.00 in a report published on Friday morning,Benzinga reports. They currently have a sector outperform rating on the biopharmaceutical company’s stock. Several other research firms have also recently issued reports on ALNY. Chardan Capital reiterated a “buy” rating and […]
